Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
A trial looking at giving R-CHOP chemotherapy with bevacizumab for diffuse large B cell lymphoma (R-CHOP-B)
This trial was looking at giving R-CHOP chemotherapy with bevacizumab to treat diffuse large B cell lymphoma. This trial was supported by Cancer Research UK.
Diffuse large B cell lymphoma (DLBCL) is a type of high grade non Hodgkin lymphoma. Doctors usually treat DLBCL with a combination of drugs - rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone. They call this R-CHOP.
In order to grow and multiply, all cells - including tumour cells - need a good blood supply. To encourage blood vessel growth, cells produce a substance called vascular endothelial growth factor (VEGF). We know from research that high levels of VEGF may affect how well R-CHOP works for some people with DLBCL.
Bevacizumab is a type of biological therapy that targets VEGF. This stops the lymphoma from developing the blood vessels that it needs in order to grow. The researchers gave bevacizumab with R-CHOP to find out if it could help people with DLBCL.
The aims of this trial were to find out
- The side effects of giving bevacizumab to people with DLBCL
- The side effects of giving bevacizumab and R-CHOP (R-CHOP-B)
- How well the combination of bevacizumab and R-CHOP worked for people with DLBCL
Summary of results
This trial was never finished so there are no results available.
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Prof David Cunningham
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
Institute of Cancer Research (ICR)
National Institute for Health Research Cancer Research Network (NCRN)
The Royal Marsden NHS Foundation Trust
This is Cancer Research UK trial number CRUK/08/029.